Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Rein Therapeutics (RNTX) Leases (2019 - 2022)

Rein Therapeutics filings provide 4 years of Leases readings, the most recent being $40000.0 for Q4 2022.

  • For the quarter ending Q4 2022, Leases fell 73.68% year-over-year to $40000.0, compared with a TTM value of $40000.0 through Dec 2022, down 73.68%, and an annual FY2022 reading of $40000.0, down 73.68% over the prior year.
  • Leases hit $40000.0 in Q4 2022 for Rein Therapeutics, down from $70000.0 in the prior quarter.
  • The five-year high for Leases was $6.5 million in Q1 2019, with the low at $40000.0 in Q4 2022.
  • Median Leases over the past 4 years was $228000.0 (2021), compared with a mean of $2.9 million.
  • The sharpest move saw Leases decreased 9.93% in 2020, then tumbled 96.81% in 2021.
  • Year by year, Leases stood at $6.1 million in 2019, then dropped by 8.42% to $5.6 million in 2020, then plummeted by 97.26% to $152000.0 in 2021, then tumbled by 73.68% to $40000.0 in 2022.
  • According to Business Quant data, Leases over the past three periods came in at $40000.0, $70000.0, and $98000.0 for Q4 2022, Q3 2022, and Q2 2022 respectively.